Idorsia Ltd. · SIX:IDIA
Idorsia — Investor Presentation (November 2025)
25 slides from Idorsia's investor presentation, November 2025
Slide 1: Idorsia – A commercial biopharma approaching profitability
Idorsia – A commercial biopharma approaching profitability Investor presentation – November 2025
Slide 2: Forward-looking statements
Forward-looking statements The information in this presentation contains certain "forward-looking statements", relating to the company's business, which can be identified by the use of forward-looking terminology such as “intend”, "estimates", "believes", "expects", "may", "are expected to", "will",
Slide 3: Idorsia today
Idorsia today Skills and legacy 3 Drugs approved Highly experienced team Proven track-record changing QUVIVIQ has strong commercial of dedicated professionals thousands of patients’ lives momentum and expanding from bench to market since founding global presence Pipeline Partnerships Rich and innova
Slide 4: Idorsia has a strong core business
Idorsia has a strong core business Strong QUVIVIQ growth driving profitability Significant upside not factored into outlook in CHF (millions) Expanded QUVIVIQ Partnership opportunities prescriber base through for pipeline assets represent evidence generation for additional sources of non-dilutive me
Slide 5: Idorsia is well-positioned for strategic growth
Idorsia is well-positioned for strategic growth Advancing a prioritized, science-driven pipeline through 1 disciplined capital allocation and strategic partnerships Accelerate commercial trajectory of QUVIVIQ by expanding: 2 reach, market presence, and medical utility Strong financial position with
Slide 6: We are advancing an innovative pipeline
We are advancing an innovative pipeline Idorsia has a strong track record Capital allocation principles drive of drug development pipeline prioritization • 3 QUVIVIQ Progressing a prioritized portfolio of first- Idorsia-discovered • TRYVIO/JERAYGO drugs approved in-class assets in areas of high unme
Slide 7: Commercial and Ph 3 assets drive growth today
Commercial and Ph 3 assets drive growth today Compound / Mechanism of action Commercially Partner Geography Phase 1 Phase 2 Phase 3 Registration / Target indication available QUVIVIQ (daridorexant) Dual orexin receptor antagonist US, EUCAN Commercialized by Idorsia in the US, Germany, Italy, Switzer
Slide 8: While we advance next wave of innovation ...
While we advance next wave of innovation ... Compound / Mechanism of action Commercially Partner Geography Phase 1 Phase 2 Phase 3 Registration / Target indication available Lucerastat Oral potential for organ protection Global Regulatory pathway to registration is in discussion with the FDA in Fabr
Slide 9: ... and fuel future value through potential partnerships
... and fuel future value through potential partnerships Compound / Mechanism of action Commercially Partner Geography Phase 1 Phase 2 Phase 3 Registration / Target indication available ACT-1016-0707 LPA 1 receptor antagonist To be determined Global Immune-mediated and fibrosis Entry-into-human pack
Slide 10: TRYVIO addresses significant medical need in difficult-to-control hypertension
TRYVIO addresses significant medical need in difficult-to-control hypertension Hypertension is #1 modifiable Aprocitentan was specifically designed to address risk factor of cardiovascular endothelin upregulation which is the key driver morbidity and premature death of difficult-to-control hypertens
Slide 11: Patients achieved rapid and durable blood pressure reductions
Patients achieved rapid and durable blood pressure reductions Randomization Re-randomization PART 1 PART 2 PART 3 155 Double- Single-blind Double-blind SiSBP (mm Hg) +/- SE blind withdrawal 150 145 Key secondary endpoint after 4 140 weeks of withdrawal 135 25 mg* vs placebo: -15.3 mmHg -17.7 mmHg -1
Slide 12: TRYVIO is the first approved innovation in HTN in close to 30 years
TRYVIO is the first approved innovation in HTN in close to 30 years Once-daily, TRYVIO is the first and only dual ERA indicated for systemic hypertension in combination with other antihypertensives PRECISION population mirrors clinical reality of resistant hypertension with comorbidities and Key dif
Slide 13: With a path to $5B peak sales + upside potential
With a path to $5B peak sales + upside potential ~26 Million ~8-13 Million ~7 Million ~0.8-1.6 Million eligible not well- readily accessible patients controlled identifiable patients ~$5 Billion patients patients Eligible Patients 30-50% not well Well-defined patient Adoption / Penetration Access an
Slide 14: Lucerastat brings a novel option to Fabry disease
Lucerastat brings a novel option to Fabry disease An oral breakthrough in substrate reduction therapy with the potential to preserve kidney function in adult patients with Fabry disease Patient population Idorsia innovation Differentiator Phase 3 Phase 3 OLE study registration program Rare genetic d
Slide 15: Daridorexant is the only DORA currently being investigated in the pediatric setting
Daridorexant is the only DORA currently being investigated in the pediatric setting • Phase 2 dose-finding study Screening Treatment Safety follow-up evaluating the efficacy and safety in 10 – 28 days 2 weeks 5 days pediatric patients aged 10 to <18 Randomization EOT FSV • Study includes patients wi
Slide 16: QUVIVIQ has a best-in-class profile to address a major medical need
QUVIVIQ has a best-in-class profile to address a major medical need Designed to have an Huge medical need optimal profile 25,000 compounds synthesized to find QUVIVIQ 8-12% adult population suffer from insomnia disorder Becoming a global brand Strong sales trajectory sales expected by 2027 countries
Slide 17: DORAs could become standard of care for insomnia disorder
DORAs could become standard of care for insomnia disorder Japan Europe Geographic expansion Market share growing > 30% Market share of DORAs in Japan 5% rapidly with introduction Expanding QUVIVIQ reach in markets with low or no market share 34% • QUVIVIQ is the only DORA in EU upside to guidance
Slide 18: The US insomnia market is large, highly dissatisfied, and ripe for disruption
The US insomnia market is large, highly dissatisfied, and ripe for disruption Descheduling of the DORA class in the US – Progress to Date ~37M • May 2022: QUVIVIQ launch o All DORAs labeled as Schedule IV due to historical precedent Total insomnia • April 2023: Idorsia formally filed Citizens Petiti
Slide 19: Idorsia has a strong financial foundation to fund our strategic priorities
Idorsia has a strong financial foundation to fund our strategic priorities ... Cash runway CHF 787m into 2028 CHF 207m Market Capitalization Liquidity* (as of Nov 11, 2025)** * Liquidity includes: 1) cash and cash equivalents of CHF 64 million as of Sep 30, 2025, 2) net proceeds of CHF 63 million fr
Slide 20: ...and is advancing toward profitability with disciplined execution
...and is advancing toward profitability with disciplined execution Idorsia-led business Status: October 2025 2023 2024 2025 CHF million proforma* as reported guidance** • Accelerating sales Revenue 32 61 130 • Reduced cost base COGS -4 -6 -15 Target commercial SG&A OPEX -358 -263 -200 profitability
Slide 21: Restructured debt is in an asset-backed vehicle
Restructured debt is in an asset-backed vehicle Idorsia Ltd* Parent / Listed on SIX (IDIA) Idorsia Pharmaceuticals Ltd Idorsia Investments SARL*** Operating company** IP Company QUVIVIQ Selatogrel CHF 150m Notes at CHF 762m new money facility due in 2048/2050 R&D Pipeline Cenerimod IP Company asset
Slide 22: Idorsia's capital allocation drives long-term value creation
Idorsia’s capital allocation drives long-term value creation Commercial Reach Capital efficiency Optimizing sales model, and utilizing Prioritizing resources to growth and partnerships, milestones, and royalties access for QUVIVIQ to support the path to profitability Profitability and capital discip
Slide 23: Key Upcoming Milestones
Key Upcoming Milestones Active areas • QUVIVIQ descheduling • Expand BD efforts of focus • Partner TRYVIO • Determine regulatory pathway for Lucerastat 2025 2026 2027 • QUVIVIQ: continuing to expand • CXCR7: initiate Phase 2 study in • Expect overall profitability commercial presence globally progre
Slide 24: Idorsia: Delivering high-value solutions for unmet medical needs
Idorsia: Delivering high-value solutions for unmet medical needs Advancing a prioritized, science-driven pipeline through 1 disciplined capital allocation and strategic partnerships Accelerate commercial trajectory of QUVIVIQ by expanding: 2 reach, market presence, and medical utility Strong financi
Slide 25: Curious to learn more? Reach out to us.
Curious to learn more? Reach out to us. George Thampy Kevin Boss SVP, Head of Investor Relations Director, Investor Relations Phone +41 58 844 10 10 investor.relations@idorsia.com 25 Idorsia – A commercial biopharma approaching profitability | November 2025